Blinklab Limited · ASX:BB1
Blinklab — JMM & ÉTHICA Innovation & Investment Insights Lunch 2024
21 slides from Blinklab's conference presentation, May 2, 2024
Slide 1: BlinkLab presents at the JMM & ÉTHICA Innovation & Investment Insights Lunch
BlinkLab presents at the JMM & ÉTHICA Innovation & Investment Insights Lunch 2 May 2024 BlinkLab Limited (ASX:BB1) (“BlinkLab”, “the Company”), an innovative digital healthcare company developing smartphone-based AI powered diagnostic tests for autism, is pleased to advise that Non-Executive Chairma
Slide 2: Early and accurate diagnosis of autism and ADHD
For personal use only Early and accurate diagnosis of autism and ADHD Using a breakthrough AI-powered smartphone platform JMM & ÉTHICA CAPITAL Innovation & Investment Lunch May 2024 Current standard BlinkLab Ltd, Sydney of 5,care: 126 Phillip Street Level NSW 2000 The diagn4stic process 1
Slide 3: Disclaimer
Disclaimer For personal use only This presentation has been prepared by BlinkLab Limited (ACN 652 901 703) (BlinkLab or Company) and contains background information about BlinkLab’s current operations at the date of this presentation. The presentation is in summary form and does not purport to be al
Slide 4: For personal use only
For personal use only Source: ndis.gov.au 3
Slide 5: Autism is a $700B market in 2024 in the US alone
Autism is a $700B market in 2024 in the US alone For personal use only ”The economic burden is significant and alarming” 1 ● Autism prevalence has grown to 2-4% among children2 ● Autism healthcare expenses world-wide are soaring3 - Costs for an autism diagnostic evaluation: $1,000 to $5,000. - Costs
Slide 6: Autism diagnosis is expensive, inaccurate, and too late
Autism diagnosis is expensive, inaccurate, and too late For personal use only Leading to poor developmental and clinical outcomes and high financial costs. Parental Autism Autism Diagnosis at Late observations screening diagnostic evaluation age 5-6 intervention Concerns arise By primary care Formal
Slide 7: BlinkLab's digital solution accelerates path to diagnosis
BlinkLab’s digital solution accelerates path to diagnosis For personal use only By bringing to market a smartphone platform for early and accurate autism diagnosis. Parental Digital Diagnostic Diagnosis at Early and personalized intervention observations screening evaluation age 2-3 and accurate mon
Slide 8: Our patented technology: neuroscience on a smartphone
Our patented technology: neuroscience on a smartphone For personal use only Minuscule facial reflexes, evoked by our app, generate a digital biomarker for autism. Smartphone-based Computer vision Scientifically-proven neurometric Facial features are tracked on the smartphone and evaluations convenie
Slide 9: How our AI technology detects autism and also ADHD
How our AI technology detects autism and also ADHD For personal use only BlinkLab precisely measures the alterations in sensory sensitivity in people with autism and ADHD. 8
Slide 10: BlinkLab is fully developed, field tested, and ready to use
BlinkLab is fully developed, field tested, and ready to use For personal use only Validated in >6,000 subjects tested globally, including people with limited access to healthcare. ● Remote testing Enables accessible and global diagnostics. ● Scalable solution Easily adaptable for clinical and divers
Slide 11: BlinkLab is collaborating with world-leading institutions
BlinkLab is collaborating with world-leading institutions Since our first product launched in 2022, we have established global partnerships with >30 academic and clinical institutes. For personal use only Prof. Samuel S. -H. Wang (Princeton University) “The BlinkLab app is easy to operate, substanti
Slide 12: Breakthrough data from large autism diagnostic study
Breakthrough data from large autism diagnostic study In our multi-center study in non-European cohort, we attained a sensitivity of 85% and specificity of 84% For personal use only Scores based on BlinkLab testing only. No additional questionnaires, such as ADOS of M-CHAT. Paper submitted for public
Slide 13: BlinkLab meets standard of care and outperforms FDA-approved digital peers
BlinkLab meets standard of care and outperforms FDA-approved digital peers For personal use only Sensitivity 85% 52% 71% Specificity 84% 19% 81% Smartphone-based Yes Yes No FDA approval Not yet De novo 510(k) We are leaders in the rapidly growing space of digital diagnostics and therapeutics. 12
Slide 14: First product to monitor the effect of therapy in real-time
First product to monitor the effect of therapy in real-time For personal use only Offers a path to even larger recurring revenues via subscription-based commercial models. Real-time Ritalin monitoring capability builds path to recurring revenue streams. 13
Slide 15: We are experts in science, tech and commercialization
We are experts in science, tech and commercialization For personal use only Our mission is to use neuroscience to improve the daily life of families with autism. Henk-Jan Boele, CEO Anton Uvarov, COO Bas Koekkoek, CSO Peter Boele, CTO Executive Director MD, PhD, Neuroscientist and MBA, PhD, Biotechn
Slide 16: We are backed up by an expert advisory board
We are backed up by an expert advisory board For personal use only World leading scientists and commercial advisors. Company Chairman Company Director Company Director Scientific advisor Scientific advisor Scientific advisor Brian Leedman Jane Morgan Richard Hopkins Prof. Samuel Wang Prof. Chris De
Slide 17: R&D Pipeline
R&D Pipeline For personal use only Our pipeline of diagnostic products, relevant development state and regulatory pathway. Pre-clinical development Early clinical development Feasibility clinical studies Pivotal clinical studies Regulatory approval Post authorization Diagnostic: BlinkLab Dx 510(k)/C
Slide 18: Important milestones
Important milestones For personal use only News pipeline: Updates on regulatory studies on autism ánd ADHD, new partnerships, new opportunities Milestone Timeframe Start of activities for FDA registrational study in autism (appointment of CRO, selection and appointment of clinical 1H 2024 sited to d
Slide 19: Capital Structure
Capital Structure For personal use only BOARD AND KEY MANAGEMENT (ASX.BB1) Public Market Overview (1 May 2024) Share Price A$0.31 Shares on issue 99,150,003 Founders' shareholding percentage 37% Founders’ options on issue @ 25c 33,750,000 Brian Leedman Henk-Jan Boele Anton Uvarov Chairman CEO Execut
Slide 20: Intellectual property
Intellectual property For personal use only Our patents prohibit other parties to conduct neurometric testing using mobile devices. BlinkLab has consistently prioritized the development We are represented by the US-based law firm, Our portfolio comprises patents filed both by Princeton and protectio
Slide 21: For Further Information Please Contact
For Further Information Please Contact For personal use only Henk-Jan Boele Brian Leedman Chief Executive Officer Non-Executive Chairman henkjan@blinklab.org brian@blinklab.org M: +31 71 799 6194 M +61 (0) 412 281 780 BlinkLab Ltd, Sydney 126 Phillip Street Level 5, NSW 2000 20
BlinkLab — JMM & ÉTHICA Innovation & Investment Insights Lunch 2024 on 6ix